Understanding how COP1 affects prostate cancer growth and treatment resistance
Official title: COP1 REGULATION OF AR SIGNALING AND PROSTATE CANCER GROWTH AND THERAPY RESISTANCE
Funded at Baylor College of Medicine · NIH-11078304 · Data updated 2026-11-12
This study is looking at how a protein called COP1 affects another protein, GATA2, which is important in prostate cancer growth and treatment resistance, to see if targeting COP1 could help improve treatment options for patients with advanced prostate cancer that doesn't respond to standard therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $485,310 |
| NIH project number | 5R01CA276341-03 |
| Project ID | NIH-11078304 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with castration-resistant prostate cancer who have not responded to standard therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates the role of COP1, an E3 ubiquitin ligase, in regulating GATA2, a protein that influences prostate cancer growth and resistance to therapies. By promoting the degradation of GATA2, COP1 may inhibit androgen receptor signaling and improve responses to treatments like docetaxel in patients with advanced prostate cancer. The study aims to uncover the molecular mechanisms behind COP1's action and its potential as a therapeutic target for patients with castration-resistant prostate cancer. Patients may benefit from insights that could lead to new treatment strategies for resistant forms of prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve treatment outcomes for patients with advanced prostate cancer.
How similar studies have gone: Other research has shown promising results in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Yang, Feng — Baylor College of Medicine
- Study coordinator: Yang, Feng
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.